Cardiocore Launches New Web site
Cardiocore announced the launch of its redesigned corporate Web site that provides users with a comprehensive view of Cardiocore's history as a top-quality, innovative core lab.
Celebrating the New Year, Cardiocore Launches a New Web Site
Site Highlights Core Lab’s Leadership in Service, Science and Data Management
Washington, DC—Cardiocore, a premier centralized cardiac testing lab, announced the launch of its redesigned corporate web site at http://www.cardiocore.com. The company’s new Internet presence provides users with a comprehensive view of Cardiocore’s history as a top-quality, innovative core lab.
“The new site delivers insights to Cardiocore’s leadership in global service, expert science and advanced data management,” said Cardiocore Vice President of Sales, Robert Goodman. He continued, “Visitors may easily find useful information about Cardiocore’s offerings such as ECG, Holter, ECHO and MUGA analyses, as well as protocol development, scientific reporting and statistics.”
Founded by a cardiac research expert and led by a clinical data management veteran, Cardiocore is often recognized as an innovator in the application of cardiac data technology. Focusing on that differentiator, Cardiocore Vice President of Marketing, Scott Satin noted, “The new site offers details about sponsor-benefiting technologies such as CardioPortal™—the company’s advanced web-based data delivery service, and HolterGateway™—Cardiocore’s leading-edge Holter data transfer system.” He added, “The new home page includes a link for direct login to CardioPortal by customers and clinical site personnel around the world.”
The newly launched web site also provides sponsors and investigators rapid access to experienced professionals located at Cardiocore’s three office locations. The company’s global headquarters is located outside Washington, DC, its US West Coast operation is in San Francisco, CA, and its European operation is based in London, UK.
About Cardiocore: Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 16 years. Services include centralized electrocardiography (ECG), Holter, echocardiography (ECHO), multigated acquisition scans (MUGA), and consulting services such as protocol development, scientific reporting and statistical analyses. The company is experienced in the design and the implementation of cardiac safety and efficacy testing in Phase I-IV and Thorough QT clinical trials. These services are supported by the company’s advanced data management system featuring the proprietary HolterGateway™ and CardioPortal™. Cardiocore’s U.S. headquarters is located in Bethesda, Maryland, its West Coast office is located in San Francisco, California, and its European subsidiary, Cardiocore Limited, is located in London, England. www.cardiocore.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
